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RESEARCH ARTICLE

The Utility of Brain Natriuretic Peptide in Patients
Undergoing an Initial Evaluation for
Pulmonary Hypertension
Sanjana Rao, Benjamin Daines, Omid Hosseini, Victor Test, Kenneth Nugent*
Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA

Abstract
Introduction: Brain natriuretic peptide (BNP) is a polypeptide released from the cardiac ventricles and has been used as
a diagnostic marker in cardiovascular diseases. Some patients with pulmonary hypertension have signiﬁcant increases in
BNP levels. This study wanted to determine whether the BNP levels in patients referred for evaluation of possible
pulmonary hypertension were associated with a particular functional class or diagnostic group.
Methods: Data were collected on patients from the Pulmonary Vascular Disease clinic undergoing right heart catheterization between 1/1/2019 and 5/20/2020. Clinical information, laboratory results including BNP, and hemodynamic
parameters were recorded.
Results: This study included 117 patients referred for evaluation for PH with measured BNP levels. The mean age was
63; the female to male ratio was 2:1, 25.4% of the patients were Hispanic. The average BNP level for the entire cohort was
4127.1 ± 11761.98 pg/ml. Patients in higher WHO functional classes tended to have higher levels of BNP, but statistical
analysis BNP showed no differences between the functional classes. Patients in WHO Group 4 had signiﬁcantly higher
BNP levels than other WHO groups. Hemodynamic group classiﬁcation demonstrated signiﬁcant differences in BNP
values between the low, intermediate, and high composite score patients.
Conclusions: Patients undergoing evaluation for pulmonary hypertension had a wide range of BNP values. Patients
with more abnormal composite hemodynamic scores higher BNP levels. Measurement of BNP provides an independent
test to help interpret patients’ descriptions of their functional limitations and to identify patients with more abnormal
hemodynamic parameters.
Keywords: Brain natriuretic peptide, Pulmonary hypertension, WHO functional class, WHO group category

1. Introduction

B

rain natriuretic peptide (BNP) is a 32 amino acid
polypeptide released primarily from the cardiac
ventricles.1,2 The 134 amino acid preoproBNP and
108 amino acid proBNP are cleaved in succession to
produce a 32 amino acid, functionally active, mature
BNP peptide and a 76 amino acid NT-proBNP.3
Brain natriuretic peptide levels are normally low
(4e35 pg/ml); however, an increase in production
and activity occurs with volume overload, such as
during cardiovascular stress.1,4 Due to its increased
production in certain disorders, measurement of
BNP levels can provide a diagnostic marker helpful

for establishing a diagnosis and possibly estimating
the severity of a cardiac disorder in some patients.
This peptide has several physiological effects in
the body. The main stimulus for BNP production
and release is ventricular stress or tension on the
cardiac walls that causes increased stretch.5 The
increased stretch and overload lead to BNP's effects,
which include decreased systemic vascular resistance, blood pressure, and pulmonary capillary
wedge pressure.5,6 Brain natriuretic peptide also
increases diuresis and causes vasodilation; these
effects may be due to the subsequent stimulation of
cGMP.6 These physiological effects have also been
demonstrated experimentally through BNP infusion
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studies, leading to the physiological effects
mentioned above.
Patients with pulmonary hypertension (PH) have
increased precapillary or postcapillary pressures
resulting in elevation of mean pulmonary artery
pressures. This syndrome can develop in multiple
clinical conditions and likely involves vascular
remodeling when longstanding.7 Patients with PH
often present with nonspeciﬁc symptoms, such as
fatigue, dizziness, chest pain, dyspnea, and edema.
An elevated BNP level would suggest a cardiac
disorder in these patients, and a very high BNP level
might suggest signiﬁcant hemodynamic stress on
cardiac ventricles. This study aims to determine the
correlations between BNP levels in patients undergoing an initial evaluation for PH and various classiﬁcations involving functional status, disease
group, and hemodynamic parameters.
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means, standard deviations, and numbers with
percentages. Brain natriuretic peptide levels had a
minimum value of 1.8 pg/ml, a maximum value of
70,000 pg/ml, and a standard deviation of 11,762 pg/
ml; results were converted to log BNP to normalize
the data set. The ShapiroeWilk test for normality
demonstrated that log BNP had a p-value of 0.105,
indicating log BNP was not statistically different
from a normal distribution, and subsequent data
analysis was conducted using log BNP values.
However, results reported as actual BNP levels in
the text since most clinicians work with these levels.
Differences in BNP between multiple groups was
analyzed using ANOVA with Tukey analysis. T-tests
were used to compare means of various groups.
Statistical signiﬁcance was set at p < 0.05.
This study was approved by the Institutional Review Board at Texas Tech University Health Sciences Center in Lubbock, Texas (L20-174).

2. Methods
Information was collected from the electronic
medical record on patients referred to the Pulmonary Vascular Disease Clinic in the Department of
Internal Medicine at Texas Tech University Health
Sciences Center in Lubbock, Texas, for evaluation
who had right heart catheterization at University
Medical Center in Lubbock between 1/1/2019 and 5/
20/2020. Demographics, clinical information, laboratory results including BNP levels, and right heart
catheterization hemodynamic parameters were
recorded. Patients were classiﬁed using the World
Health Organization (WHO) Functional Classiﬁcation (FC), WHO Group Classiﬁcation, and a hemodynamic composite score based on right heart
catheterization values (Table 1).8
Statistical analysis was performed using IBM
SPSS Statistics. Results were summarized using
Table 1. Hemodynamic summary score classiﬁcation.
Hemodynamic Parameter

Value Range

Assigned
Score (1e3)

Right Atrial Pressure
(mm Hg)

<8
8e14
>14
2.5
2.0e2.4
<2.0
>65
60e65
<60

1
2
3
1
2
3
1
2
3

Cardiac Index
(L/min/m2)
Mixed Venous
Oxygen Saturation (%)
Composite scores
Low score group
Mid score group
High score group
Modiﬁed from reference 8.

3,4,5
6,7
8,9

3. Results
This study included 117 patients presenting for
evaluation for PH with measured BNP levels. The
mean age was 62.8 ± 14.5 years, 67.8% of patients
were female, and 25.4% were Hispanic. These patients presented with multiple pre-existing conditions; the most frequent co-morbidities were
hypertension (96 patients, 82.1%), diabetes (52,
44.4%), obstructive sleep apnea (47, 40.2%), coronary
artery disease (27, 23.1%), and atrial ﬁbrillation (25,
21.4%). Most patients (112, 95.7%) presented with
shortness of breath, and 59 (50.4%) presented with
edema. Patients were classiﬁed using the WHO FC
and the WHO Group classiﬁcation after evaluation.
The mean BNP for the entire cohort was
4127.1 ± 11761.98 pg/ml with normal value of BNP
less than124 pg/ml in our laboratory. Patients in
higher WHO functional classes tended to have
higher levels of BNP (Table 2), but statistical analysis showed no differences between functional
groups. Patients in WHO Group 4 had signiﬁcantly
higher BNP levels (p value < 0.05) than other WHO
Groups (Table 2).
There was a signiﬁcant correlation between the
BNP and the mean pulmonary artery pressure, the
right atrial pressure, the pulmonary capillary wedge
pressure, and the pulmonary vascular resistance
(Table 3). These relationships indicate that a BNP of
276.7 pg/ml predicts a mean pulmonary artery
pressure greater 25 mmHg, BNP of 571.5 pg/ml
predicts a right atrial pressure 10 mmHg, a BNP of
691.8 pg/ml predicts pulmonary capillary wedge
pressure 18 mmHg, and a BNP of 606.7 pg/ml
predicts pulmonary vascular resistance 3 Wood
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Table 2. WHO functional class and group category BNP levels.

WHO Functional Class
FC* I, n ¼ 2
FC II, n ¼ 5
FC III, n ¼ 69
FC IV, n ¼ 29
WHO Group Category
Group 1, n ¼ 50
Group 2, n ¼ 30
Group 3, n ¼ 7
Group 4, n ¼ 4
Group 2 þ 3***, n ¼ 22

BNP <124
pg/ml

BNP >124
pg/ml

BNP
mean ± SD

1
1
20
3

1
4
49
26

37; 3030**
1800 ± 1649
4809 ± 14701
3497 ± 4360

15
5
3
0
0

35
25
4
4
22

2139 ± 3643
3947 ± 12695
470 ± 664
42683 ± 33814
3609 ± 7273

* FC- functional class; ** Individual values; ***Group 2 þ 3 patients had clinically important cardiac disease and respiratory
disease and the best explanation for their PH was uncertain.

units. These calculations were made assuming a
linear relationship between BNP and each variable,
respectively. Patients were then classiﬁed into
groups based on the hemodynamics score developed after cardiac catheterization (Table 1).8 BNP
levels in both the intermediate and high composite
score groups were signiﬁcantly higher than the BNP
levels in the low composite score group (Table 3).
Patients in WHO Group 1 (n ¼ 55) had a mean
pulmonary artery pressure of 40.4 ± 16.3 mmHg;
patients in WHO Group 2 (n ¼ 56) had a mean
pulmonary artery pressure of 35.7 ± 10.1 mmHg
(P ¼ 0.036). Patients in WHO Group 1 had a mean
pulmonary
artery
wedge
pressure
of
11.8 ± 5.3 mmHg; patients in WHO Group 2 had a
mean pulmonary artery wedge pressure of
21.6 ± 15.1 mmHg (p < 0.001). Patients in WHO
Group 1 had positive correlations between BNP
levels and right atrial pressures (r ¼ 0.398,
p ¼ 0.004), pulmonary artery systolic pressures
(r ¼ 0.309, p ¼ 0.026), pulmonary artery diastolic
pressures (r ¼ 0.362, p ¼ 0.008), mean pulmonary
artery pressures (r ¼ 0.353, p ¼ 0.01), and right atrial

indices (r ¼ 0.621, p ¼ 0.006). Patients in WHO
Group 2 had positive positive correlations between
BNP levels and right ventricular systolic pressures
(r ¼ 0.333, p ¼ 0.018) and pulmonary artery systolic
pressures (r ¼ 0.342, p ¼ 0.015).

4. Discussion
Our results demonstrate that BNP levels have
some important associations in a heterogeneous
group of patients referred for the evaluation of
possible PH. BNP levels had signiﬁcant positive
correlations with multiple hemodynamic parameters, including mean pulmonary artery pressures
and right atrial pressures. In addition, BNP levels
were higher in patients with more abnormal composite hemodynamic scores. Finally, although the
group size was small, patients in WHO Group 4 had
signiﬁcantly higher BNP levels. Therefore, BNP
levels can help predict hemodynamic parameters in
patients referred for pulmonary hypertension evaluation, and patients with very high BNP levels
should be evaluated carefully for the possibility of
chronic thromboembolic disease.
Several parameters have been used to measure
the severity of PH in patients; these include the
WHO FC, the 6-min walk test (6MWT), and formal
exercise testing. Safdar et al. reviewed the correlation between BNP and the 6MWT in 38 patients with
pulmonary arterial hypertension and found that
patients with baseline BNP levels greater than
100 pg/ml had a decreased 6MWT (349 ± 64 m) in
comparison to patients with BNP levels less than
100 pg/ml who had a 6MWT of 428 ± 80 m.9 The
6MWT was decreased in patients in higher WHO
FC, and patients with higher BNP levels had a
shorter time to clinical deterioration and had
increased mortality. In this study, there were no
deﬁnite associations between BNP levels and hemodynamic variables measured at baseline and at a

Table 3. Correlation between BNP levels and hemodynamic parameters.
Correlation between log BNP and hemodynamic parameters
Hemodynamic Parameter
Mean Pulmonary Artery Pressure (mm Hg)
Right Atrial Pressure (mm Hg)
Pulmonary Capillary Wedge Pressure (mm Hg)
Pulmonary Vascular Resistance (Wood Units)

R Value
0.475
0.427
0.206
0.186

Hemodynamic composite score group and BNP values
Hemodynamic Group Score#
Low (Group 3,4,5), n ¼ 68
Intermediate (Group 6,7), n ¼ 39
High (Group 8,9), n ¼ 10

BNP pg/ml Mean ± SD
3060.67 ± 9978.24
624.44 ± 15529.74*
3525.00 ± 2957.65**

#- see Table 1 for hemodynamic score classiﬁcation; *p ¼ 0.002; **p ¼ 0.006 in comparison to the group.

P Value
0.0000000543
0.000002
0.027
0.044

1-year
follow-up.9
Helgeson
retrospectively
reviewed information on 138 patients with pulmonary arterial hypertension.10 Patients with BNP
levels >240 pg/ml were in higher FC and had more
abnormal hemodynamic parameters, larger right
atria and right ventricles on echocardiograms,
shorter 6MWT distances, and increased mortality.
Leuchte et al. measured BNP levels in patients
with 28 patients with pulmonary arterial hypertension and found strong correlations between BNP
levels and WHO FC, particularly Groups II and III,
and an inverse relationship with the 6MWT.11 There
was a positive direct correlation with pulmonary
artery pressures, right atrial pressures, and pulmonary vascular resistance. These authors suggested
that the BNP level parallels the degree of the hemodynamic abnormality in these patients, and serial measurements might help improve the
management of these patients. Nagaya et al.
demonstrated that prostacyclin therapy decreased
BNP levels, providing an indicator for responses to
changes in drug management.12
Leuchte et al. reviewed risk stratiﬁcation and
assessment of prognosis in patients with pulmonary
arterial hypertension.13 Their analysis indicated that
patients with a mortality risk of greater than 10% at
1 year had a higher WHO FC (IV), a reduced 6-min
walk distance (<165 m), and an elevated BNP
(>300 pg/ml). They noted these parameters provide
noninvasive methods for risk classiﬁcation and are
particularly useful for follow-up evaluations. Lewis
and co-authors have reviewed the use of point-ofcare testing for either BNP or NTeproBNP for the
management of patients with pulmonary arterial
hypertension.14 The methods used for this testing
typically can provide results in 10e20 min, and
currently available point-of-care test devices have
excellent correlations with clinical laboratory
results.
The WHO classiﬁcation includes patients with
cardiac disease and increased post capillary pressures (Group 2), patients with parenchymal lung
disease and/or obstructive sleep apnea (Group 3),
and patients with chronic thromboembolic vascular
disease (Group 4). These patients usually present
with signiﬁcant dyspnea and exercise limitation and
frequently have additional comorbidity, especially if
older.15 Determining the predominant disease process and the pathophysiologic mechanism for pulmonary hypertension, if present, can be difﬁcult.
Patients with chronic interstitial lung disease usually have signiﬁcant dyspnea which could reﬂect
their lung disease or could also reﬂect a contribution
from pulmonary vascular disease. Leuchte et al.
analyzed the clinical signiﬁcance of BNP levels in
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patients with PH associated with pulmonary ﬁbrosis
and found that elevated BNP levels with a strong
correlation between BNP and pulmonary vascular
resistance. There were no signiﬁcant correlations
between lung function parameters and BNP levels.16
This study supports the use of BNP as a potential
diagnostic marker for moderate to severe PH in
patients with interstitial lung disease. Ruocco et al.
reported the use of BNP levels with diffusion capacity of the lung for carbon monoxide and echocardiography to identify pulmonary hypertension in
patients with interstitial lung disease.17 Reesink
et al. studied BNP levels in patients with chronic
thromboembolic pulmonary hypertension and
found that these levels were increased in patients
with right ventricular dysfunction, especially with
an ejection fraction of less than 0.30.18 Iwanaga et al.
studied patients with chronic systolic and diastolic
heart failure who were clinically stable at the time of
catheterization.19 These patients had a wide range of
BNP levels which were signiﬁcantly higher in patients with systolic heart failure. Patients with systolic heart failure and diastolic heart failure had
similar left ventricular end-diastolic pressures, but
patients with systolic heart failure had signiﬁcantly
higher left ventricular end-diastolic wall stress. That
parameter correlated best with elevated BNP levels.
Consequently, in this study BNP levels helped
identify the underlying pathophysiology in patients
with chronic heart failure.
Our study involves a retrospective review of
clinical information developed on patients referred
to pulmonary vascular disease clinic for evaluation
of possible pulmonary hypertension. This was a
heterogeneous group of patients and not limited to
patients with pulmonary arterial hypertension.
This study has several limitations. First, there were
very few patients in WHO FC I and II; this is not
necessarily unexpected since patients with limited
symptoms may not undergo right heart catheterization, an inclusion criterion for this study. However, FC III and IV had a signiﬁcant number of
patients and had higher BNP levels than patients in
FC I and II. Second, the information in this study is
based on evaluations done at one clinical center
and may not be generalizable. Third, in general,
BNP levels were measured at the time of initial
evaluation which included right heart catheterization. However, longer time intervals between the
laboratory test and a right heart catheterization
could reduce correlations. Fourth, although there
were signiﬁcant correlations between BNP measurements and right heart hemodynamic measurements, the r values for these correlations were
relatively low.
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5. Conclusions
Patients with PH can have very high BNP levels in
comparison to normal individuals. In our cohort of
patients with pulmonary hypertension, BNP tended
to be higher in patients with more functional limitation. In addition, BNP levels in patient groups
based on hemodynamic classiﬁcation were
increased in the groups with more abnormal hemodynamic parameters, demonstrating the utility of
BNP measurements as a clinical marker for PH
severity. Therefore, the initial BNP level can help
clinicians make decisions regarding the next steps in
the evaluations of patients who are often have
complex clinical presentations and should
encourage more assessment of their hemodynamic
status. Finally, BNP levels provide a simple method
to follow responses to change in treatment and to
follow the progression in these patients.
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